Outcomes of Concurrent Chemo-Radiotherapy in Locally Advanced Cervical Cancer.

CCRT is considered the standard of care in LACC since 1999. However there are few reports of results of this treatment in the common practice in developing countries were this disease is most frequent.

Official Title

Outcomes of Concurrent Chemo-Radiotherapy (CCRT) in Locally Advanced Cervical Cancer (LACC). Results of a retrospective analysis of a single institution.

Conditions

Study Type

Retrospective analysis of a single institution.

Study Design

The records of all patients (pts) with LACC treated in our service between 1998 and 2002 were reviewed. Overall survival (OS) and Disease Free Survival (DFS) were the main outcomes of our review.

Further Details

Results: The records of 284 pts with LACC treated in our institution were reviewed. 142 pts were treated with CCRT from 1998 to 2002. The pts characteristics were: Stage: (%) IB 2 (1.4), IIA 3 (2.1), IIB 60 (42.2), IIIA 3 (2.1), IIIB 69 (48.5), IVA 2 (1.4). The median age was: 47 (21-79) The histology was squomous in all pts. The chemotherapy regimen (C) used were: between 1998 and 1999: Ifosfamide (I), Cisplatin (P) +/- Bleomicine (B), (BIP/IP) in 27 pts (19) and since 1999: weekly P (40 mg/m2) in 94 pts. (66) and weekly P/Gemcitabine (G) in 21 pts (15) All pts had a planed external beam radiation therapy with a cobalt unit (5040 cGy in 5.6 weeks) and a single application of brachytherapy (30-35 Gy on point A).122 pts (85) had a complete radiation as planed. There were one death related to treatment with BIP CT and there were no toxic deaths with the others regimens, 5 pts (3.5) abandon treatment, all with weekly P. The median follow up was: 24 months (m)(1-83). 44 pts were early lost in follow up (less than 10 months. The overall survival was 83%. with a DFS 59% (84/142). 13 pts (9) progressed and 39 pts (27) recurred, the median TTP was 15 m (4-40). The DFS by stages was: IIB 65%, IIIB/IVA 56% and by C regimen was: BIP/IP 55%, P/G 76% and P 56%. The median follow up for BIP/IP 35 m, P/G 33 m and P 19 m. Conclusions: CCRT is feasible in a community hospital of a developing country. However, the DFS seems to be below to that reported in randomized trials, especially for weekly cisplatin and radiation.

Study Start

Eligibility & Criteria

Total Enrolment

284

Contact Details

J. Zarba, P. Gonzalez Jazey, R. Pedruzzi, L. de Gregorio, J. G. Chavanne, E. Muela, R. Audi, S. Forneris, P. Gonzalez2005 ASCO Annual Meeting: Gynecological Cancer.